Updates in the Management of Melanoma
12 ESCO credits
03.10.2014 - 04.10.2014
Bucharest, Romania
COURSES AND SEMINARS
Description
Chairs: O. Simionescu, RO - A. Testori, IT
Host Chairs: A. Blidaru, RO - R. Cosgarea, RO
Seminar Coordinator: S. Gandini, IT
Over the last few decades, there has been a considerable increase in the number of new melanoma cases, with the relative incidence doubling every 15 years. In western countries, this increase in incidence has been correlated with a stable mortality as early diagnosis campaigns have sensitized populations towards the knowledge of this disease, whilst in eastern countries the increase in incidence is unfortunately correlated to a relative increase in mortality mainly due to late diagnosis. No other cancer has shown such a high percentage increase in incidence over the last 40 years. Identification of thinner melanomas has contributed to an increase in the rate of survival that is documented in all epidemiological surveys.
Knowledge of risk factors should also be given credit for helping prevention as well as the importance of early diagnosis and the campaigns against artificial UV exposure. The prohibition of the use of sunbeds for people under 18 years old is one of the most important results from these campaigns.
This Seminar is designed for physicians interested in the field of melanoma from diagnosis to surgical approaches. Moreover, the seminar will focus on the use of new therapies in advanced stages of the disease.
Experts from different disciplines will foster a multidisciplinary approach to melanoma in its various stages of diagnosis and treatment.
OBJECTIVES
| • | To provide an overview of the state-of-the-art and the most advanced scientific results on diagnostic and therapeutic approaches to melanoma. With particular attention to dermatological topics and surgical techniques. | |
| • | Increase knowledge of epidemiology, molecular-genetic, biological and immunological melanoma | |
| • | Increase knowledge of the most recent medical therapeutic approaches | |
| • | Improvement of multidisciplinary approaches in the management of melanoma patients |
.
General information
ORGANISING SECRETARIAT
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Programme and Organisation
Roberta Ventura - rventura@eso.net - Tel: +39 02 85464532
Registrations
Elena Fiore - efiore@eso.net - Tel: +39 02 85464529
VENUE
Crowne Plaza Bucharest
1 Poligrafiei Blvd.
Bucharest, Romania
Phone: +40 21 2240034
Website: www.crowneplaza.ro
BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.
Loss of badge causes loss of registration.
OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.
INSURANCE
The organizers bear no responsibility for untoward events in relation to the participation in the seminar. Participants are advised to take out their own personal and travel insurance coverage.
CME ACCREDITATION AND CERTIFICATES
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The Updates in the management of Melanoma seminar has been assigned 11 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Information on the process to convert EACCME credit to AMA credit can be found at www.amaassn.org/go/internationalcme.
SPONSORS
ESO wishes to extend its appreciation to Bristol-Myers Squibb for having granted its participation and support to the Updates in the Management of Melanoma seminar.
.
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Programme and Organisation
Roberta Ventura - rventura@eso.net - Tel: +39 02 85464532
Registrations
Elena Fiore - efiore@eso.net - Tel: +39 02 85464529
VENUE
Crowne Plaza Bucharest
1 Poligrafiei Blvd.
Bucharest, Romania
Phone: +40 21 2240034
Website: www.crowneplaza.ro
BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.
Loss of badge causes loss of registration.
OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.
INSURANCE
The organizers bear no responsibility for untoward events in relation to the participation in the seminar. Participants are advised to take out their own personal and travel insurance coverage.
CME ACCREDITATION AND CERTIFICATES
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The Updates in the management of Melanoma seminar has been assigned 11 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Information on the process to convert EACCME credit to AMA credit can be found at www.amaassn.org/go/internationalcme.
SPONSORS
ESO wishes to extend its appreciation to Bristol-Myers Squibb for having granted its participation and support to the Updates in the Management of Melanoma seminar.
.
Faculty list
FACULTY
F. Bacanu, Saint Mary Clinical Hospital, Bucharest, RO
A. Blidaru, “Prof. Al. Trestioreanu” Institute of Oncology, Bucharest, RO
G. Botti, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT
M. Cook, Royal Surrey County Hospital NHS Foundation Trust, Guilford, UK
R. Cosgarea, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, RO
M. Costache, University Hospital of Bucharest, RO
G. Dindelegan, Spitalul Clinic Judetean De Urgenta, Cluj-Napoca, RO
D. Dobrosavljevic, University of Belgrade, RS
R. Dzodic, Institute of Oncology and Radiology of Serbia, Belgrade, RS
S. Gandini, European Institute of Oncology, IT
C. Garbe, University Medical Center, Tuebingen, DE
S.R. Georgescu, Victor Babes Clinical Hospital, Bucharest, RO
H. Gogas, University of Athens, GR
D. Jinga, University Hospital Bucharest, RO
P. Lorigan, Christie Hospital NHS Foundation Trust, Manchester, UK
S. Matkovic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
I. Olah, University of Szeged, HU
G. Pellacani, University of Modena and Reggio Emilia, Modena, IT
M. Sajin, University Hospital Bucharest, RO
O. Simionescu, Colentina Clinical Hospital, Bucharest, RO
D. Stanculeanu, „Prof. Al. Trestioreanu” Institute of Oncology, Bucharest, RO
A. Testori, European Institute of Oncology, IT
A. Udrea, Medisprof Day Oncology Hospital, Cluj-Napoca, RO
A. van Akkooi, Netherlands Cancer Institute, Amsterdam, NL
F. Bacanu, Saint Mary Clinical Hospital, Bucharest, RO
A. Blidaru, “Prof. Al. Trestioreanu” Institute of Oncology, Bucharest, RO
G. Botti, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT
M. Cook, Royal Surrey County Hospital NHS Foundation Trust, Guilford, UK
R. Cosgarea, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, RO
M. Costache, University Hospital of Bucharest, RO
G. Dindelegan, Spitalul Clinic Judetean De Urgenta, Cluj-Napoca, RO
D. Dobrosavljevic, University of Belgrade, RS
R. Dzodic, Institute of Oncology and Radiology of Serbia, Belgrade, RS
S. Gandini, European Institute of Oncology, IT
C. Garbe, University Medical Center, Tuebingen, DE
S.R. Georgescu, Victor Babes Clinical Hospital, Bucharest, RO
H. Gogas, University of Athens, GR
D. Jinga, University Hospital Bucharest, RO
P. Lorigan, Christie Hospital NHS Foundation Trust, Manchester, UK
S. Matkovic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
I. Olah, University of Szeged, HU
G. Pellacani, University of Modena and Reggio Emilia, Modena, IT
M. Sajin, University Hospital Bucharest, RO
O. Simionescu, Colentina Clinical Hospital, Bucharest, RO
D. Stanculeanu, „Prof. Al. Trestioreanu” Institute of Oncology, Bucharest, RO
A. Testori, European Institute of Oncology, IT
A. Udrea, Medisprof Day Oncology Hospital, Cluj-Napoca, RO
A. van Akkooi, Netherlands Cancer Institute, Amsterdam, NL
Programme
3 October
| SESSION I: PREVENTION AND DIAGNOSIS Chairs: O. Simionescu, RO – D. Dobrosavljevic, RS | ||
| 8:30 | Welcome message: Clinical management of cutaneous melanoma in Romania | |
| 8:50 | Genetics and familial melanoma S. Gandini, IT | |
| 9:10 | Epidemiology and risk factors for melanoma S. Gandini, IT | |
| 9:30 | Clinical diagnosis: test on Clinical cases 15-20 images G. Pellacani, IT | |
| 9:50 | Instrumental diagnosis: dermoscopy G. Garbe, DE | |
| 10:10 | Instrumental diagnosis: confocal microscopy G. Pellacani, IT | |
| 10:30 | Coffee break | |
| 10:45 | Clinical cases: review test on the same images G. Pellacani, IT | |
| 11:05 | Melanoma management in Romania D. Jinga, RO | |
| 11:25 | Our experience in melanoma today S. Georgescu, RO | |
| 11:45 | The role of dermato oncology society in Romania R. Cosgarea, RO | |
| 12:05 | Discussion | |
| SESSION II: HISTOPATHOLOGY AND AJCC CLASSIFICATION Chairs: M. Sajin, RO - M. Costache, RO | ||
| 12:30 | AJCC classification - TNM, 2009, preview of the new 2014 classification C. Garbe, DE | |
| 12:50 | Rare and unusual clinical primary melanoma presentations G. Pellacani, IT | |
| 13:10 | Histopathology of primary melanoma M. Cook, UK | |
| 13:30 | Lunch break | |
| 14:30 | Histopathology of atypical melanocitic lesions G. Botti, IT | |
| 14:50 | Histopathology of sentinel node M. Cook, UK | |
| 15:10 | Discussion | |
| SESSION III: SURGERY Chairs: R. Dzodic, RS - A. Blidaru, RO | ||
| 15:30 | Surgery on primary melanoma and sentinel node biopsy A. Testori, IT | |
| 15:50 | Surgical treatment on lymph nodal metastases A. van Akkooi, NL | |
| 16:10 | Survival role of n-ratio and quality control on TLND A. Testori, IT | |
| 16:30 | Coffee break | |
| 16:45 | SNB and ELND in cutaneous melanoma: 10 years of experience in Bucharest Institute of Oncology A. Blidaru, RO | |
| 17:05 | SNB experience in Serbia R. Dzodic, RS | |
| 17:25 | Surgical guide lines in Romania G. Dindelegan, RO | |
| 17:45 | History of adjuvant treatments on melanoma and actual standard (debate) Pro H. Gogas, GR Cons P. Lorigan, UK | |
| 18:15 | Discussion | |
| 18:45 | Satellite symposium (to be confirmed) | |
4 October
| SESSION IV: LOCO-REGIONAL THERAPIES FOR IN TRANSIT METASTASES, SURGERY AND CHEMOTHERAPY FOR STAGE III B, C & IV DISEASE Chairs: C. Garbe, DE - S. Matkovic, RS | ||
8:30 | Limb perfusion with/without TNF A. Testori, IT | |
8:50 | Electrochemoterapy A. Testori, IT | |
9:10 | Surgery for stage IV melanoma A. van Akkooi, NL | |
9:30 | Systemic treatment for stage IV melanoma A. Udrea, RO | |
| 9:50 | Clinical cases | |
| - Learning from mistakes-errors in melanoma approach: dermatology (O. Simionescu, RO) | |
| SESSION V: TARGET THERAPY Chairs: D. Stanculeanu, RO - I. Olah, HU | ||
| 11:00 | Target identification: molecular analysis methods G. Botti, IT | |
| 11:20 | Target therapy update on B-Raf+/- Mek inhibitors P. Lorigan, UK | |
| 11:40 | Target therapy update on N-Ras and C-Kit inhibitors H. Gogas, GR | |
| 12:00 | Prevention and management of side effects of target therapy R. Cosgarea, RO | |
| 12:20 | Round table: Target therapy in east Europe: how can patients reach these drugs? Panelists: H. Gogas, GR- P. Lorigan, UK - S. Matkovic, RS - I. Olah, HU - D. Stanculeanu, RO | |
| 13:00 | Discussion | |
| 13:30 | Lunch break | |
| SESSION VI: IMMUNOTHERAPY IN STAGE IV Chair: F. Bacanu, RO - D. Jinga, RO | ||
| 14:30 | Mechanism of action of ipilimumab and PD-1 H. Gogas, GR | |
| 14:50 | Indications for treatment with ipilimumab P. Lorigan, UK | |
| 15:10 | Immune related side effects and management of ipilimumab side effects H. Gogas, GR | |
| 15:30 | Recist immune response evaluation parameters and PD-1 studies report P. Lorigan, UK | |
| 15:50 | Clinical cases of efficacy and complications with IPI+/-PD- H. Gogas, GR | |
| 16:10 | Discussion | |
| 16:30 | Closing remarks | |
.